trending Market Intelligence /marketintelligence/en/news-insights/trending/cxqqgjchx14ib1y5chvcmq2 content esgSubNav
In This List

KemPharm's pain drug Apadaz gets US FDA approval

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


KemPharm's pain drug Apadaz gets US FDA approval

The U.S. Food and Drug Administration approved KemPharm Inc.'s new drug application for its painkiller Apadaz.

The agency has approved the drug for the short-term, no more than 14 days, management of acute pain severe enough to require an opioid drug and for which alternative treatments are not adequate.

Apadaz is a combination of the company's prodrug benzhydrocodone, which is chemically inert or inactive on its own, and acetaminophen.